Merck known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.
Rockwell Automation, Inc., the world's largest company dedicated to industrial automation and digital transformation, announced the launch of FactoryTalk® PharmaSuite® 12.00. The latest release of its manufacturing execution system (MES) is designed to support the unique needs of regulated pharmaceutical and...
Bruker Corporation announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innovations in miniscope design, nVista 2P offers enhanced resolution for sub-cellular imaging and mapping of neural circuit dynamics.
AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform.
Bruker Corporation announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays.
Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, announces the positive results from the SPEED1 survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT).
Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing.
Accuray Incorporated announced that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States.
Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration.
Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.